Welcome to our dedicated page for AREV LIFE SCIENCES GLOBAL news (Ticker: AREVF), a resource for investors and traders seeking the latest updates and insights on AREV LIFE SCIENCES GLOBAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AREV LIFE SCIENCES GLOBAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AREV LIFE SCIENCES GLOBAL's position in the market.
AREV Life Sciences Global Corp. has appointed Kevin Phelps, CPA, as the Chief Operating Officer to facilitate its growth and expansion. Phelps, with over 40 years of experience in biotechnology and business, served in various executive roles, including as CEO and CFO. The company also announced a retention warrant offering for its senior management, including a pricing structure and exercise provisions. Insiders' participation in this offering qualifies as a 'related party transaction' but is exempt from formal valuation. AREV focuses on delivering therapeutic solutions through innovative drug design and collaborations.
AREV Life Sciences Global Corp. (CSE: AREV, OTC: AREVF) has announced its initial research engagement with TransBIOTech, a supported preclinical research organization. This collaboration aims to explore the therapeutic potential of cannabinoids and address public health challenges. Leveraging proprietary extraction technologies, AREV plans to conduct studies on immune modulation and phytomedicinal therapeutics. Initial studies will focus on understanding the pharmacological properties of compounds, with a goal of satisfying regulatory requirements for human studies and eventual commercialization.
AREV Life Sciences Global Corp. has completed its fungi inoculation lab in Coquitlam, focusing on Lion's Mane mushrooms. The company achieves a 10% extraction yield, regarded as exceptional by experts. This milestone enhances revenue streams and positions AREV for potential applications in health products and drug development. Lion's Mane's compounds may offer various health benefits, including brain protection and anti-inflammatory properties. However, human studies are still required to confirm efficacy.
AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) announced new acquisitions and product developments on Feb. 17, 2022. Key appointments include Douglas Sorocco to the scientific advisory committee and IP council, enhancing corporate capacity. The company is focused on its ready-to-use therapeutic food, SUSTAINN, amid a global famine crisis. Additionally, AREV extended its partnership with Strategic Health Resources LLC to gain formulary inclusion for SUSTAINN. The company also issued 100,000 stock options to key personnel at a price of $0.29 each.
FAQ
What is the market cap of AREV LIFE SCIENCES GLOBAL (AREVF)?
